Brain metastases of breast cancer

References

• Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52, 2349–2354 (1983).
   PubMed Web of Science ®Google Scholar
• DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 44, 1913–1918 (1979).
   PubMed Web of Science ®Google Scholar
• Sneed PK, Larson DA, Wara WM. Radiotherapy for cerebral metastases. Neurosurg. Clin. N. Am. 7, 505–515 (1996).
   PubMed Web of Science ®Google Scholar
• Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972–2977 (2003).
   PubMed Web of Science ®Google Scholar
• Melisko M, Sneed P, Moore D, Rugo H. Predicting survival in breast cancer patients with brain metastasis. Proc. Am. Soc. Clin. Oncol. 22, 42 (2003).
   Google Scholar
• Sparrow GE, Rubens RD. Brain metastases from breast cancer: clinical course, prognosis and influence of treatment. Clin. Oncol. 7, 291–301 (1981).
   PubMed Web of Science ®Google Scholar
• Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer 91, 639–643 (2004).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Cristofanilli M, Strom EA et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101, 1760–1766 (2004).
   PubMed Web of Science ®Google Scholar
• Carey LA, Ewend MG, Metzger R et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res. Treat. 88, 273–280 (2004).
   PubMed Web of Science ®Google Scholar
• Van Pelt A, Elledge R, Allred D, Mohsin S, Gutierrez M, Chang J. Phase II study of neoadjuvant trastuzumab plus docetaxel for locally advanced and metastatic breast cancer that overexpresses HER-2/neu: a preliminary report. Breast Cancer Res. Treat. 441a (2002).
   Google Scholar
• Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int. J. Cancer 49, 650–655 (1991).
   PubMed Web of Science ®Google Scholar
• van’t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J. Neuro-oncol. 44, 275–281 (1999).
   PubMed Web of Science ®Google Scholar
• Regina A, Demeule M, Laplante A et al. Multi-drug resistance in brain tumors: roles of the blood–brain barrier. Cancer Metastasis Rev. 20, 13–25 (2001).
   PubMed Web of Science ®Google Scholar
• Blasberg RG, Groothuis DR. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin. Oncol. 13, 70–82 (1986).
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multi-drug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84, 7735–7738 (1987).
   PubMed Web of Science ®Google Scholar
• Demeule M, Labelle M, Regina A, Berthelet F, Beliveau R. Isolation of endothelial cells from brain, lung, and kidney: expression of the multi-drug resistance P-glycoprotein isoforms. Biochem. Biophys. Res. Commun. 281, 827–834 (2001).
   PubMed Web of Science ®Google Scholar
• Sawaya R, Hammoud M, Schoppa D et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42, 1044–1055 (1998).
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485–1489 (1998).
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494–500 (1990).
   PubMed Web of Science ®Google Scholar
• Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann. Neurol. 33, 583–590 (1993).
   PubMed Web of Science ®Google Scholar
• Wronski M, Arbit E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer 80, 1746–1754 (1997).
   PubMed Web of Science ®Google Scholar
• Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int. J. Radiat. Oncol. Biol. Phys. 54, 810–817 (2002).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 39, 789–796 (1989).
   PubMed Web of Science ®Google Scholar
• Pavy JJ, Denekamp J, Letschert J et al. EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother. Oncol. 35, 11–15 (1995).
   PubMed Web of Science ®Google Scholar
• Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 45, 427–434 (1999).
   PubMed Web of Science ®Google Scholar
• Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665–1672 (2004).
   PubMed Web of Science ®Google Scholar
• Flickinger JC. Radiotherapy and radiosurgical management of brain metastases. Curr. Oncol. Rep. 3, 484–489 (2001).
   PubMedGoogle Scholar
• Sneed PK, Lamborn KR, Forstner JM et al. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int. J. Radiat. Oncol. Biol. Phys. 43, 549–558 (1999).
   PubMed Web of Science ®Google Scholar
• Bindal AK, Bindal RK, Hess KR et al. Surgery versus radiosurgery in the treatment of brain metastasis. J. Neurosurg. 84, 748–754 (1996).
   PubMed Web of Science ®Google Scholar
• O’Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O’Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 55, 1169–1176 (2003).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Grewaal D, Redmond MD et al. Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide. Cancer Chemother. Pharmacol. 32, 368–372 (1993).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Lu K, Benjamin RS et al. Concentration of vinblastine in human intracerebral tumor and other tissues. J. Neuro-oncol. 1, 139–144 (1983).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Mikhael NZ, Nair RC et al. Platinum concentrations in human autopsy tumor samples. Am. J. Clin. Oncol. 11, 152–158 (1988).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Richard MT, Hugenholtz H et al. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J. Neuro-oncol. 2, 133–139 (1984).
   PubMed Web of Science ®Google Scholar
• Twelves CJ, Souhami RL, Harper PG et al. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br. J. Cancer 61, 147–150 (1990).
   PubMed Web of Science ®Google Scholar
• Relling MV, Pui CH, Sandlund JT et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356, 285–290 (2000).
   PubMed Web of Science ®Google Scholar
• Riva M, Landonio G, Defanti CA, Siena S. The effect of anticonvulsant drugs on blood levels of methotrexate. J. Neuro-oncol. 48, 249–250 (2000).
   PubMed Web of Science ®Google Scholar
• Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58, 832–839 (1986).
   PubMed Web of Science ®Google Scholar
• Colleoni M, Graiff C, Nelli P et al. Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. Am. J. Clin. Oncol. 20, 303–307 (1997).
   PubMed Web of Science ®Google Scholar
• Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69, 972–980 (1992).
   PubMed Web of Science ®Google Scholar
• Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85, 1599–1605 (1999).
   PubMed Web of Science ®Google Scholar
• Lamond JP, Mehta MP, Boothman DA. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. J. Neuro-oncol. 30, 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24, 256–260 (2001).
   PubMedGoogle Scholar
• Gruschow K, Klautke G, Fietkau R. Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. Eur. J. Cancer 38, 367–374 (2002).
   PubMed Web of Science ®Google Scholar
• Lange OF, Scheef W, Haase KD. Palliative radio-chemotherapy with ifosfamide and BCNU for breast cancer patients with cerebral metastases. A 5-year experience. Cancer Chemother. Pharmacol. 26(Suppl.), S78–S80 (1990).
   Google Scholar
• Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am. J. Clin. Oncol. 24, 421–424 (2001).
   PubMed Web of Science ®Google Scholar
• Rivera E, Valero V, Francis D et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Breast Cancer Res. Treat. 88, S68 (2004) (Abstract 1079).
   Google Scholar
• van der Gaast A, Alexieva-Figusch J, Vecht C, Verweij J, Stoter G. Complete remission of a brain metastasis to third-line hormonal treatment with megestrol acetate. Am. J. Clin. Oncol. 13, 507–509 (1990).
   PubMed Web of Science ®Google Scholar
• Pors H, von Eyben FE, Sorensen OS, Larsen M. Longterm remission of multiple brain metastases with tamoxifen. J. Neuro-oncol. 10, 173–177 (1991).
   PubMed Web of Science ®Google Scholar
• Salvati M, Cervoni L, Innocenzi G, Bardella L. Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases. Tumori 79, 359–362 (1993).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J. Neuro-oncol. 24, 299–301 (1995).
   PubMed Web of Science ®Google Scholar
• Lien EA, Wester K, Lonning PE, Solheim E, Ueland PM. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer 63, 641–645 (1991).
   PubMed Web of Science ®Google Scholar
• Ozdogan M, Samur M, Bozcuk HS et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J. Clin. Oncol. 33, 229–231 (2003).
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348, 2431–2442 (2003).
   PubMed Web of Science ®Google Scholar
• Roselli CE, Resko JA, Stormshak F. Estrogen synthesis in fetal sheep brain: effect of maternal treatment with an aromatase inhibitor. Biol. Reprod. 68, 370–374 (2003).
   PubMedGoogle Scholar
• Park J, Tripathy D, Campbell M, Esserman L. Biological therapy of breast cancer. Biodrugs 14, 221–246 (2000).
   Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized antiHER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639–2648. (1999).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Lower E, Blau R, Bismayer J et al. Increased brain metastases detected in metastastic breast cancer patients receiving Herceptin. Breast Cancer Res. Treat.69, 271 (2001) (Abstract 357).
   Google Scholar
• Lower E, Blau R, Drosick D, Danneman W, Brennan L, Hawley D. Brain metastases during Herceptin therapy: improved survival compared to patients not treated with Herceptin. Clin. Breast Cancer 4, 114–119 (2003).
   PubMedGoogle Scholar
• Loebbecke M, Fchs I, Evers K et al. Efficacy of Herceptin treatment of brain metastases in women with HER-2 overexpressing breast cancer. Breast Cancer Res. Treat. 69, 302 (2001) (Abstract 521).
   Google Scholar
• Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101, 810–816 (2004).
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J. Clin. Oncol. 18, 2349–2351 (2000).
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med. 345, 621–622 (2001).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Olson JD, Raizer JJ et al. A Phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J. Neuro-oncol. 53, 259–265 (2001).
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Kosmidis P et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann. Oncol. 12, 249–254 (2001).
   PubMed Web of Science ®Google Scholar
• Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. 20, 3644–3650 (2002).
   PubMed Web of Science ®Google Scholar
• Magda D, Lepp C, Gerasimchuk N et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Oncol. Biol. Phys. 51, 1025–1036 (2001).
   PubMed Web of Science ®Google Scholar
• Miller RA, Woodburn KW, Fan Q et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin. Cancer Res. 7, 3215–3221 (2001).
   PubMed Web of Science ®Google Scholar
• Mehta MP, Shapiro WR, Glantz MJ et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J. Clin. Oncol. 20, 3445–3453 (2002).
   PubMed Web of Science ®Google Scholar
• Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21, 2529–2536 (2003).
   PubMed Web of Science ®Google Scholar
• Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized Phase III trial. J. Clin. Oncol. 22, 157–165 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw E, Scott C, Suh J et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J. Clin. Oncol. 21, 2364–2371 (2003).
   PubMed Web of Science ®Google Scholar
• Stea B, Suh J, Shaw E et al. Efaproxiral (Efaproxyn) as an adjunct to whole brain radiation therapy for the treatment of brain metastases originating from breast cancer: updated survival results of the randomized REACH (RT-009) study. Breast Cancer Res. Treat. 88 (2004) (Abstract 4064).
   Google Scholar
• Suh J, Stea BD, Kresl JJ et al. Results from a subgroup analysis of patients with metastatic breast cancer (MBC) in a Phase 3, randomized, open-label, comparative study of standard whole brain radiation therapy (WBRT) with supplemental oxygen, with or without RSR13, in patients with brain metastases. Breast Cancer Res. Treat. 82, 41–42 (2003) (Abstract 175).
   Google Scholar
• Goetz A, Denis L, Rowinsky E et al. Phase I and pharmacokinetic study of RPR116258A, a novel taxane derivative, administered intravenously over 1 h every three weeks. Proc. Am. Soc. Clin. Oncol. 21, (2001) (Abstract 419).
   Google Scholar
• Amadori A, Santoro A, Hoffken K et al. A Phase II trial of the novel taxane BAY 59–8862 in patients with advanced taxane-resistant breast cancer. Proc. Am. Soc. Clin. Oncol. 22, 44 (2003) (Abstract 176).
   Google Scholar
• Namba Y, Kijima T, Yokota S et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin. Lung Cancer 6, 123–128 (2004).
   PubMedGoogle Scholar
• Hotta K, Kiura K, Ueoka H et al. Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46, 255–261 (2004).
   PubMed Web of Science ®Google Scholar
• Gumerlock MK, Belshe BD, Madsen R, Watts C. Osmotic blood–brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J. Neuro-oncol. 12, 33–46 (1992).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Grahovac Z, Hugenholtz H et al. Feasibility study of intraarterial vs. intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors. J. Neuro-oncol. 17, 71–79 (1993).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Grahovac Z, Hugenholtz H et al. Intraarterial mitomycin-C for recurrent brain metastases. Am. J. Clin. Oncol. 10, 432–436 (1987).
   PubMed Web of Science ®Google Scholar
• Fellner S, Bauer B, Miller DS et al. Transport of paclitaxel (Taxol) across the blood–brain barrier in vitro and in vivo. J. Clin. Invest. 110, 1309–1318 (2002).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Sandberg DI, Edgar MA, Souweidane MM. Convection-enhanced delivery into the rat brainstem. J. Neurosurg. 96, 885–891 (2002).
   PubMed Web of Science ®Google Scholar
• Mardor Y, Roth Y, Lidar Z et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 61, 4971–4973 (2001).
   PubMed Web of Science ®Google Scholar
• Groothuis DR, Benalcazar H, Allen CV et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res. 856, 281–290 (2000).
   PubMed Web of Science ®Google Scholar
• Yang W, Barth RF, Adams DM et al. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res. 62, 6552–6558 (2002).
   PubMed Web of Science ®Google Scholar
• Bankiewicz KS, Eberling JL, Kohutnicka M et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using prodrug approach. Exp. Neurol. 164, 2–14 (2000).
   PubMed Web of Science ®Google Scholar
• Nguyen JB, Sanchez-Pernaute R, Cunningham J, Bankiewicz KS. Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 12, 1961–1964 (2001).
   PubMed Web of Science ®Google Scholar
• Grossi PM, Ochiai H, Archer GE et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin. Cancer Res. 9, 5514–5520 (2003).
   PubMed Web of Science ®Google Scholar
• Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 95–99 (2002).
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189–207 (2001).
   PubMedGoogle Scholar
• Robert N, Vogel C, Henderson I et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin. Oncol. (2005) (In Press).
   Google Scholar
• Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist. Update 6, 271–279 (2003).
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB et al. AntiHER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172–1181 (2002).
   PubMed Web of Science ®Google Scholar
• Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83, 1029–1037 (1995).
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Koukouraki S, Fezoulidis I et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer 83, 1281–1286 (2000).
   PubMed Web of Science ®Google Scholar
• Del Prete S, Caraglia M, Addeo R, Costanzo R, Faiola V, Facchini G. Pegylated liposomal doxorubicin plus temozolomide in the salvage treatment of brain metastases: a feasibility study. Proc. Am. Soc. Clin. Oncol.22, 119 (2003) (Abstract 474).
   Google Scholar
• Mamot C, Nguyen JB, Pourdehnad M et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J. Neuro-oncol. 68, 1–9 (2004).
   PubMed Web of Science ®Google Scholar
• Saito R, Bringas JR, McKnight TR et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 64, 2572–2579 (2004).
   PubMed Web of Science ®Google Scholar
• Lu W, Su J, Kim LS et al. Active specific immunotherapy against occult brain metastasis. Cancer Res. 63, 1345–1350 (2003).
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J. Immunother. 26, 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 90, 1115–1124 (1999).
   PubMed Web of Science ®Google Scholar
• Gerosa M, Nicolato A, Foroni R et al. Gamma knife radiosurgery for brain metastases: a primary therapeutic option. J. Neurosurg. 97, 515–524 (2002).
   PubMed Web of Science ®Google Scholar
• Petrovich Z, Yu C, Giannotta SL, O’Day S, Apuzzo ML. Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J. Neurosurg. 97, 499–506 (2002).
   PubMed Web of Science ®Google Scholar
• Firlik KS, Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for brain metastases from breast cancer. Ann. Surg. Oncol. 7, 333–338 (2000).
   PubMed Web of Science ®Google Scholar
• Amendola BE, Wolf AL, Coy SR, Amendola M, Bloch L. Gamma knife radiosurgery in the treatment of patients with single and multiple brain metastases from carcinoma of the breast. Cancer J. 6, 88–92 (2000).
   PubMed Web of Science ®Google Scholar
• Schoeggl A, Kitz K, Ertl A, Reddy M, Bavinzski G, Schneider B. Prognostic factor analysis for multiple brain metastases after gamma knife radiosurgery: results in 97 patients. J. Neuro-oncol. 42, 169–175 (1999).
   PubMed Web of Science ®Google Scholar
• Simonova G, Liscak R, Novotny J Jr, Novotny J. Solitary brain metastases treated with the Leksell gamma knife: prognostic factors for patients. Radiother. Oncol. 57, 207–213 (2000).
   PubMed Web of Science ®Google Scholar
• Vesagas TS, Aguilar JA, Mercado ER, Mariano MM. Gamma knife radiosurgery and brain metastases: local control, survival, and quality of life. J. Neurosurg. 97, 507–510 (2002).
   PubMed Web of Science ®Google Scholar